Stay updated on Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe history adds that the study is no longer recruiting participants, and notes Revision: v3.6.0, replacing the prior v3.5.5 in the revision history.SummaryDifference0.2%

- Check9 days agoChange DetectedThe page footer now shows Revision: v3.5.5, replacing Revision: v3.5.4. This metadata update indicates the site's revision version is current and does not alter the study history content.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page's revision label updates from Revision: v3.5.3 to Revision: v3.5.4. This indicates a newer version of the page rendering.SummaryDifference0.0%

- Check51 days agoChange DetectedUpdates the ClinicalTrials.gov page’s displayed software/UI revision number from v3.5.2 to v3.5.3. This reflects a platform release rather than a change to the study record itself.SummaryDifference0.0%

- Check58 days agoChange DetectedAdded Revision: v3.5.2 and deleted Revision: v3.5.0 from the history.SummaryDifference0.0%

- Check72 days agoChange DetectedDifference0.0%

Stay in the know with updates to Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.